Leaderboards/Breast Cancer Treatment Studies

Breast Cancer Treatment Studies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

Angela N. Giaquinto

American Cancer Society

Unknown

The Netherlands Cancer Institute

Jean Ogier du Terrail

Atkins (United States)

Yuzhou Cai

Chinese University of Hong Kong

Rikke Nørgaard Pedersen

Aarhus University Hospital

Annemiek K. E. van Hemert

The Netherlands Cancer Institute

Duo Zuo

Tianjin Medical University Cancer Institute and Hospital

Kevin Boehm

Memorial Sloan Kettering Cancer Center

Papers

Breast cancer statistics 2024

CA A Cancer Journal for Clinicians|2024

645 cit.

The global burden of breast cancer among women of reproductive age: a comprehensive analysis

Scientific Reports|2025

62 cit.

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

Nature Communications|2025

40 cit.

Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 −2020)

European Journal of Cancer|2024

18 cit.

Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol

The Breast|2025

17 cit.

Iodine Seed−Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer

JAMA Oncology|2025

10 cit.

Lobular breast cancer statistics, 2025

Cancer|2025

9 cit.

Global, Regional, and National Burden of Smoking-Related Diseases and Associations With Health Workforce Distribution, 1990–2021: Analysis From the Global Burden of Disease Study 2021

International Journal of Public Health|2025

7 cit.

Publication in Public Health (2025) [6 citations, W4409182281]

Public Health|2025

6 cit.

FedECA: federated external control arms for causal inference with time-to-event data in distributed settings

Nature Communications|2025

4 cit.

Emerging Leaders

Drafting the new consensus

Papers

Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal

Cancer Research|2023

853 cit.

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes

JAMA Oncology|2023

498 cit.

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

npj Breast Cancer|2022

97 cit.

Implications of missing data on reported breast cancer mortality

Breast Cancer Research and Treatment|2022

61 cit.

Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer

Journal of Clinical Oncology|2023

42 cit.

Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

JNCI Journal of the National Cancer Institute|2024

31 cit.

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

The Oncologist|2023

25 cit.

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

Cancer Medicine|2022

22 cit.

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities

The Oncologist|2024

20 cit.

Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast

Journal of Surgical Oncology|2022

18 cit.

Current Senior Leaders

Wrote the book, still writing it

Papers

Molecular portraits of human breast tumours

Nature|2000

16.3k cit.

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Oncology|2013

13.2k cit.

Gene expression profiling predicts clinical outcome of breast cancer

Nature|2002

9.6k cit.

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

New England Journal of Medicine|2004

6.4k cit.

Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer

New England Journal of Medicine|2002

6.2k cit.

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

Histopathology|1991

6.2k cit.

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine|2005

5.4k cit.

Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer

New England Journal of Medicine|2002

4.4k cit.

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Annals of Oncology|2011

3.9k cit.

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Science|1990

3.8k cit.

Reagents for Breast Cancer Treatment Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Agilent/DakoEvidence 60

Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1

Cited in 10 papers

#M7240

View Evidence →

Leica BiosystemsEvidence 73

Anti-Ki67 Antigen Monoclonal Antibody, FITC Conjugated, Clone MM1

Cited in 8 papers

#NCL-Ki67-FITC

View Evidence →

Cell Signaling TechnologyEvidence 65

Bim (C34C5) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 8 papers

#94805$465

View Evidence →

🌟 All-Time

Most validated

c-erbB-2, c-neu

Agilent/DakoEvidence 63

Progesterone Receptor

Estrogen Receptor ?